Frontiers in psychiatry · 2026
The effect of bright light therapy on glycemic control and cortisol rhythmicity in depression: a randomized controlled trial.
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fang Jie, Li Xinyu, Zhu Shukun, Hu Qinghong, Wang Ting, Yu Jiakuai, Qin Ximing, Zhu Daomin
Аннотация
BACKGROUND: Depressed patients with comorbid metabolic disorders have poorer quality of life and prognosis. Pharmacological interventions carries risks of liver and kidney toxicity, which highlights the need for safer non-pharmacological alternatives. Experimental data suggest that light exposure modulates cortisol secretion, thereby influencing metabolic outcomes in depression. We hypothesized that bright light therapy may ameliorate metabolic disturbances by modulating cortisol secretion.
METHODS: In this randomized controlled trial, hospitalized patients with depression were assigned to receive either bright light therapy (BLT) or dim-light control condition. The pre-specified primary endpoint was the change in fasting blood glucose (FBG) and cortisol rhythm indices from baseline to post-treatment. Secondary endpoints included changes in other glycolipid parameters, and scores on the Hamilton Depression (HAMD) and Anxiety (HAMA) scales. Treatment effects were evaluated using linear mixed-effects models with baseline adjustment.
RESULTS: After the 2-week intervention, the BLT group showed a significant reduction in fasting blood glucose (95% CI: 0.280 to 0.600; p < 0.001) and cortisol mesor (95% CI: -2.677 to -0.064; p = 0.040) compared to the control group. Within the BLT group, the change in FBG was positively associated with the change in cortisol mesor after adjusting for covariates (β = 0.053, 95% CI: 0.016 to 0.122, p = 0.036).
CONCLUSIONS: The findings of this study support a potential mechanism whereby BLT modulates cortisol rhythmicity, which in turn may contribute to improved glycemic control, pointing to its potential therapeutic benefit for addressing metabolic disturbances in depression.
CLINICAL TRIAL REGISTRATION: https://www.chictr.org.cn/bin/project/edit?pid=260569, identifier ChiCTR2500097364.
METHODS: In this randomized controlled trial, hospitalized patients with depression were assigned to receive either bright light therapy (BLT) or dim-light control condition. The pre-specified primary endpoint was the change in fasting blood glucose (FBG) and cortisol rhythm indices from baseline to post-treatment. Secondary endpoints included changes in other glycolipid parameters, and scores on the Hamilton Depression (HAMD) and Anxiety (HAMA) scales. Treatment effects were evaluated using linear mixed-effects models with baseline adjustment.
RESULTS: After the 2-week intervention, the BLT group showed a significant reduction in fasting blood glucose (95% CI: 0.280 to 0.600; p < 0.001) and cortisol mesor (95% CI: -2.677 to -0.064; p = 0.040) compared to the control group. Within the BLT group, the change in FBG was positively associated with the change in cortisol mesor after adjusting for covariates (β = 0.053, 95% CI: 0.016 to 0.122, p = 0.036).
CONCLUSIONS: The findings of this study support a potential mechanism whereby BLT modulates cortisol rhythmicity, which in turn may contribute to improved glycemic control, pointing to its potential therapeutic benefit for addressing metabolic disturbances in depression.
CLINICAL TRIAL REGISTRATION: https://www.chictr.org.cn/bin/project/edit?pid=260569, identifier ChiCTR2500097364.